CY1110683T1 - Anti-egfr αντισωματα - Google Patents

Anti-egfr αντισωματα

Info

Publication number
CY1110683T1
CY1110683T1 CY20101100346T CY101100346T CY1110683T1 CY 1110683 T1 CY1110683 T1 CY 1110683T1 CY 20101100346 T CY20101100346 T CY 20101100346T CY 101100346 T CY101100346 T CY 101100346T CY 1110683 T1 CY1110683 T1 CY 1110683T1
Authority
CY
Cyprus
Prior art keywords
egfr
egfr antibodies
antigen
binding fragments
antibodies
Prior art date
Application number
CY20101100346T
Other languages
English (en)
Inventor
Catherine Brautigam Beidler
Alain Philippe Vasserot
Jeffry Dean Watkins
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP06837044A external-priority patent/EP1951759B1/en
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of CY1110683T1 publication Critical patent/CY1110683T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Η παρούσα εφεύρεση περικλείει ειδικά ως προς τον EGFR μονοκλωνικά αντισώματα ή τμήματα τους που προσδένουν αντιγόνο. Αυτά τα αντισώματα, ή τα τμήματα τους που προσδένουν αντιγόνο έχουν υψηλή συγγένεια για τον EGFR, αναστέλλουν την ενεργοποίηση του EGFR και είναι χρήσιμα για τη θεραπεία των καρκίνων που διαμεσολαβούνται από τον EGFR.
CY20101100346T 2005-11-12 2010-04-16 Anti-egfr αντισωματα CY1110683T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73536305P 2005-11-12 2005-11-12
EP06837044A EP1951759B1 (en) 2005-11-12 2006-11-06 Anti-egfr antibodies

Publications (1)

Publication Number Publication Date
CY1110683T1 true CY1110683T1 (el) 2015-06-10

Family

ID=42664729

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20101100346T CY1110683T1 (el) 2005-11-12 2010-04-16 Anti-egfr αντισωματα

Country Status (1)

Country Link
CY (1) CY1110683T1 (el)

Similar Documents

Publication Publication Date Title
CY1124965T1 (el) Μονοκλωνα αντισωματα κατα κλαουδινης-18 για τη θεραπεια του καρκινου
CY1116886T1 (el) C-met αντισωματα
CY1123883T1 (el) Ανθρωποποιημενα αντισωματα κατα της liv-1 και χρηση αυτων για τη θεραπευτικη αντιμετωπιση του καρκινου
CY1122091T1 (el) Μορια δεσμευσης-cd37 και ανοσοσυζευγματα εξ αυτων
CY1115572T1 (el) Αντι cxcr4 αντισωματα και χρηση αυτων για τη θεραπεια καρκινου
DK1951759T3 (da) Anti-EGFR-antistoffer
CY1119591T1 (el) Πρωτεϊνες ειδικης συνδεσης και χρησεις αυτων
CY1120065T1 (el) Ανθρωπινα αντισωματα για ton erbb 2
CY1119794T1 (el) Ενωσεις αναστολεων ε-σελεκτινης
CY1124412T1 (el) Aνti-dkk-1 αντισωματα
CY1119127T1 (el) Επιτοποι σκληροστινης
CY1119956T1 (el) Μονοκλωνικα anti-gt468 αντισωματα για θεραπεια καρκiνου
CY1114658T1 (el) Πρωτεϊνες δεσμευσης αντιγονου του αυξητικου παραγοντα τυπου επιδερμικου αυξητικου παραγοντα προσδεσης στην ηπαρινη
CY1116167T1 (el) Φαρμακευτικeς συνθεσεις κατευθυνομενες σε υποδοχεις erb-b1
CO6612264A2 (es) Proteinas terapeuticas de la union a dll 4
CY1115321T1 (el) Αντισωματα κατευθυνομενα προς αγγειοποιητινη-1 και αγγειοποιητινη-2 και χρηση αυτων
MX2022014914A (es) Compuestos de interaccion con glicanos y metodos de uso.
EA201791050A1 (ru) Конъюгаты антител и лекарственных средств
MX2022011732A (es) Conjugados de farmacos y anticuerpos anti-ccr7.
DK2097453T3 (da) Monoklonale antistoffer mod humant Anti-Müllerian Hormon type II receptor (AMHR-II)
CY1125102T1 (el) Αντιγονοδεσμευτικες πρωτεϊνες που ενεργοποιουν τον υποδοχεα λεπτινης
ATE526987T1 (de) Dr5-antikörper und deren verwendung
EA201070636A1 (ru) Ингибирование рецептора белка, стимулирующего макрофаги (ron), и способы его лечения
EA200701448A1 (ru) Специфически связывающаяся с крипто-антигеном человека молекула (варианты), композиция на ее основе (варианты), способ получения молекулы, способ лечения посредством молекулы (варианты) и способ ингибирования крипто-экспрессии в клетке больного
CY1120123T1 (el) Μονοκλωνικα αντισωματα κατα της gt468 για τη θεραπεια του καρκινου